Colorectal Cancer Clinical Trial
Official title:
The Acceptability and Feasibility of a Diet and Physical Activity Intervention to Prevent Recurrence in Colorectal Cancer Survivors: a Phase 2 Study
Background - Colorectal cancer (CRC) incidence is increasing at an alarming rate in Hong
Kong. A recent report concluded physical activity (PA) protects against colon cancer and
foods low in dietary fibre, red meat and processed meat cause CRC. Yet, the influence of
lifestyle factors on cancer outcome (i.e. recurrence and survival rates) in CRC survivors is
largely unknown.
Objectives & hypothesis - Our study aims to evaluate the acceptability of two behavioural
interventions for CRC survivors intended to improve cancer outcome and designed to (1)
increase PA levels and (2) reduce consumption of a Western diet.
The investigators hypothesize that the proposed interventions are (1) efficacious in
changing the two targeted behaviours; and (2) acceptable to CRC survivors.
Settings and methods - Phase 2 feasibility trial. Two hundred and twenty-four CRC survivors
within 12 months of completion of cancer treatment and without evidence of
persistent/recurrent disease will be recruited from four public hospitals in Hong Kong after
informed consent. Subjects will be randomized in a 2x2 factorial design for the two targeted
behaviours prescribed over 12 months. Primary outcome measure is whether the target levels
of PA and dietary intake could be met at the end of intervention. Secondary outcome measures
include: (1) magnitude of changes in PA level and dietary intakes; (2) rates and
determinants of compliance; (3) facilitators and barriers to behavioural change; (4)
measurement of theoretical constructs underlying PA and dietary interventions; (5) possible
health benefits and side effects (PA-associated injury and nutritional deficiency) arising
from the interventions. Outcome will be assessed at baseline, 6 months into intervention and
then at 0, 6 and 12 months post-intervention.
Impact - If proven feasible, our intervention programme would pave way for a large
randomized controlled trial testing the effect of PA and diet on the treatment outcome of
CRC.
Background - Colorectal cancer (CRC) incidence is increasing at an alarming rate in Hong
Kong. A recent World Cancer Research Fund (WCRF) report concluded physical activity (PA)
protects against colon cancer and foods low in dietary fibre, red meat and processed meat
cause CRC. Yet, the influence of lifestyle factors on cancer outcome (i.e. recurrence and
survival rates) in CRC survivors is largely unknown. Our literature review showed a paucity
of published studies on lifestyle intervention in CRC survivors; none had investigated the
effect of such intervention on cancer outcomes.
With advances in treatment, CRC survivors live longer. Many of them are motivated to make
lifestyle changes. However, our qualitative research has shown a huge service gap in the
provision of appropriate PA and dietary advice to CRC survivors. Many patients were unaware
of the link between PA and diet with CRC outcome but most demonstrated acceptance of
lifestyle intervention. Yet, there is currently no scientifically-based evidence to allow
firm recommendations to be made.
Objectives & hypothesis - Our study aims to evaluate the acceptability of two behavioural
interventions for CRC survivors intended to improve cancer outcome and designed to (1)
increase PA levels (to 60 minutes of moderate PA 5 days/week) and (2) reduce consumption of
a Western diet (<5 servings of red/processed meat weekly and 2 servings of refined grain
daily).
We hypothesize that the proposed interventions are (1) efficacious in changing the two
targeted behaviours; and (2) acceptable to CRC survivors with compliance rates of about 80%.
Settings and methods - The study follows the Medical Research Council Framework for the
design and evaluation of complex interventions. Phases 0 and 1 (funded by WCRF) have been
completed.
This application seeks funding for a Phase 2 feasibility trial. Two hundred and twenty-four
CRC survivors within 12 months of completion of cancer treatment and without evidence of
persistent/recurrent disease will be recruited from four public hospitals in Hong Kong after
informed consent. Subjects will be randomized in a 2x2 factorial design for the two targeted
behaviours prescribed over 12 months. Primary outcome measure is whether the target levels
of PA and dietary intake could be met at the end of intervention. Secondary outcome measures
include: (1) magnitude of changes in PA level and dietary intakes; (2) rates and
determinants of compliance by questionnaire; (3) facilitators and barriers to behavioural
change by questionnaire; (4) measurement of theoretical constructs underlying PA and dietary
interventions by questionnaire; (5) possible health benefits (body composition, physical
fitness, quality of life and mood) and side effects (PA-associated injury and nutritional
deficiency) arising from the interventions. Outcome will be assessed at baseline, 6 months
into intervention and then at 0, 6 and 12 months post-intervention (i.e. at baseline, 6, 12,
18 and 24 months after the start of intervention).
Impact - To the best of our knowledge, this is the first behavioural intervention model
targeting PA and reduced consumption of a Western diet in CRC survivors. If proven feasible,
our intervention programme would pave way for a large randomized controlled trial testing
the effect of PA and diet on the treatment outcome of CRC.
;
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |